The KingMed Diagnostics (Boao,Hainan) Co., Ltd (or Boao KingMed), based in the Hainan Boao International Medical Tourism Pilot Zone, is funded and established by Guangzhou KingMed Diagnostics Group Co., Ltd. (KingMed Diagnostics, SSE: 603882), a pioneer and leader of the Independent Clinical Laboratories (ICL) industry in China.

KingMed Diagnostics is a high-tech service enterprise specialized in ICL and pathological diagnosis, offering high-quality ICL solutions to a range of medical institutions. By aligning with international benchmarks, furthering self-dependent innovations, and translating scientific discoveries, KingMed has developed the capacity to conduct more than 3,000 tests for clinical and scientific research purposes, receiving over 100 million medical specimens each year. Over years of sample accumulation and data standardization, the company built a world-leading repository for healthcare data. Such a repository contains a great amount of samples for East Asian ethnicity, based on which KingMed aspires to advance original innovation in the fields of In Vitro Diagnostics (IVD) and AI-enabled diagnostics.

Making use of its 17,578m2 facilities, along with the technical platform and talent resources offered by KingMed, Boao KingMed is dedicated to importing latest diagnostic technologies that have been approved overseas. In the meantime, such a program allows for the exploration of new cooperative models with IVD and pharmaceutical companies and other up-stream enterprises in China and abroad.

Seizing the opportunities provided by the Pilot Zone’s special access policies, Boao KingMed aims to set the standards for ICL sector in the region, providing international-level and first-class diagnostic services to benefit the Boao Medical Pilot Zone, Hainan Province, and China, as well as bringing China’s healthcare industry to another level.